Symbol

    loading  Checking for direct PDF access through Ovid

Abstract

BACKGROUND:

The haploidentical hematopoietic stem cell transplantation is an effective treatment method of hematologic malignancies. It is very useful for increasing the successful rate of stem cell transplantation to find an appropriate donor rapidly.

OBJECTIVE:

To compare the clinical effect of parental haploidentical hematopoietic stem cell transplantation for treatment of hematologic malignancies.

METHODS:

Ninety-two patients with hematologic malignancies who underwent parental haploidentical hematopoietic stem cell transplantation were divided into four groups, including father-to-son transplantation group, father-to-daughter transplantation group, mother-to-son transplantation group and mother-to-daughter transplantation group. The incidence of graft versus host disease, recurrence rate, and 2-year disease-free survival and overall survival rate were compared between groups.

RESULTS AND CONCLUSION:

Engraftment was successful in a total of 92 patients. There were no significant differences of incidence of acute graft versus host disease, chronic graft versus host disease and recurrence rate among four groups (P > 0.05). Significant difference was observed in the occurrence of III-IV acute graft versus host disease, 2-year disease-free survival rate and 2-year overall survival rate among four groups (P < 0.05). The incidence of III-IV acute graft versus host disease in father-to-son transplantation group and mother-to-daughter transplantation group was significantly lower than that in father-to-daughter transplantation group and mother-to-son transplantation group; 2-year disease-free survival rate and 2-year overall survival rate in the father-to-son transplantation group and mother-to-daughter transplantation group were higher than those in the father-to-daughter transplantation group and mother-to-son transplantation group. Parental haploidentical hematopoietic stem cell transplantation is safe and feasible, and the same gender of patients and donors have better effect than the different genders of patients and donors.

RESULTS AND CONCLUSION:

Wan DM, Shi CC, Xie XS, Sun L, Sun H. Parental donor in haploidentical hematopoietic stem cell transplantation for treatment of hematologic malignancies. Zhongguo Zuzhi Gongcheng Yanjiu. 2013;17(13):1753-1760.

Related Topics

    loading  Loading Related Articles